정맥영양요법 관련 유해반응 분석Analysis of Adverse Reactions Associated with Parenteral Nutrition Use in Korea
- Other Titles
- Analysis of Adverse Reactions Associated with Parenteral Nutrition Use in Korea
- Authors
- SERA LEE; MIYOUNG OCK; SEONGHEE KIM; 김현아
- Issue Date
- Jun-2017
- Publisher
- 한국정맥경장영양학회
- Citation
- Journal of Clinical Nutrition, v.9, no.1, pp 16 - 20
- Pages
- 5
- Journal Title
- Journal of Clinical Nutrition
- Volume
- 9
- Number
- 1
- Start Page
- 16
- End Page
- 20
- URI
- https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/17721
- DOI
- 10.15747/jcn.2017.9.1.16
- ISSN
- 2289-0203
2383-7101
- Abstract
- Purpose: To evaluate the clinical manifestations of adverse drug reactions (ADRs) of parenteral nutrition (PN) use in Korea.
Methods: The Korean Adverse Event Reporting System (KAERS) database records in 2015 on PN-treated patients were used. ADRs classified as “certain,” “probable,” and “possible” based on the WHO-Uppsala Monitoring Centre criteria were analyzed.
Results: In total, 21,436 ADRs from 2,346 patients were included for analysis. The mean patient age was 57.1 years and the mean number of ADRs per patient was 9.1. ADRs were reported frequently with amino acids solutions (682 events, 40.8%), followed by combinations products (519 events, 31.1%), and fat emulsions (363 events, 21.7%). The frequent ADRs were gastrointestinal (507 events, 30.3%), skin (343 events, 20.5%), general disorders (239 events, 14.3%), and central/peripheral nervous system disorders (165 events, 9.9%). The common clinical symptoms were nausea (321 events, 19.2%), vomiting (105 events, 6.3%), and vein pain (102 events, 6.1%). Serious ADRs accounted for 220 patients (9.4%) and dyspnea was the most frequent clinical manifestation.
Conclusion: This study analyzed the KAERS data in 2015 from patients treated with PN and revealed gastrointestinal and skin disorders to be the leading ADRs.
- Files in This Item
-
Go to Link
- Appears in
Collections - 약학대학 > 약학부 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.